Grail, Inc. (GRAL) Stock Price & Analysis
Grail, Inc. (GRAL) fell 3.58% to USD 67.84 as of July 25, 2026 at 20:15 UTC, according to Nexqual real-time market data.
GRAL last closed at USD 70.36; the session ranged USD 67.47–72.11 on volume of 314,872 shares. Market capitalization is $2.91B, with a 52-week range of USD 29.95–118.84 (NMS). Source: Nexqual, July 25, 2026 at 20:15 UTC.
Key Statistics (as of July 25, 2026 at 20:15 UTC)
| Price | USD 67.84 |
|---|---|
| Change | ▼ 3.58% (down) |
| Previous Close | USD 70.36 |
| Open | USD 72.11 |
| Day Range | USD 67.47 – 72.11 |
| 52-Week Range | USD 29.95 – 118.84 |
| Volume | 314,872 shares |
| Market Cap | $2.91B |
| Exchange | NMS |
Technical Analysis (GRAL)
Nexqual's technical model rates GRAL "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 20:15 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.98 (neutral) |
| vs SMA50 | Above (USD 66.18) |
| MACD | 1.55 (positive) |
Analyst Ratings (GRAL)
Wall Street analysts rate GRAL "Buy" based on 8 analysts, with a mean price target of USD 70.13 (range USD 56–88), per Nexqual as of July 25, 2026 at 20:15 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 70.13 |
| High Target | USD 88 |
| Low Target | USD 56 |
| Buy / Hold / Sell | 4 / 5 / 0 |
Earnings (GRAL)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -2.43 |
| Revenue Estimate | $42.40M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.37 vs est -1.96 ▲ beat |
| 2025-12-31 | USD -2.44 vs est -2.53 ▲ beat |
| 2025-09-30 | USD -2.46 vs est -3.27 ▲ beat |
| 2025-06-30 | USD -3.18 vs est -3.56 ▲ beat |
Source: Nexqual, July 25, 2026 at 20:15 UTC.
Financials & Fundamentals (GRAL)
| Total Revenue | $156.12M |
|---|---|
| Revenue Growth (YoY) | +28.10% |
| Gross Margin | +49.28% |
| Operating Margin | -332.88% |
| Profit Margin | -253.22% |
| ROE | -16.09% |
| Debt / Equity | 2.04 |
| Current Ratio | 11.74 |
| Total Cash | $823.11M |
| Total Debt | $51.03M |
| Free Cash Flow | $-107.75M |
Source: Nexqual, July 25, 2026 at 20:15 UTC.
Financial Health Score (GRAL)
Nexqual rates Grail, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 20:15 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $823M cash vs $51M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$108M, burning cash |
| Efficiency | Critical — ROE -16%, ROA -11.4% |
Ownership (GRAL)
| Insider Ownership | +5.23% |
|---|---|
| Institutional Ownership | +83.50% |
| Shares Outstanding | 42.92M |
| Float | 33.44M |
| Short % of Float | +18.32% |
Source: Nexqual, July 25, 2026 at 20:15 UTC.
Leadership (GRAL)
Grail, Inc. is led by Joshua J. Ofman M.D., M.S.H.S (age 60), CEO & Director, per Nexqual as of July 25, 2026 at 20:15 UTC.
| CEO & Director | Joshua J. Ofman M.D., M.S.H.S (age 60) |
|---|---|
| CFO & Head of Corporate Development | Aaron Freidin (age 46) |
| Senior Vice President of Global Development & Operations | Paul Ciccolella |
| Chief Technology Officer | Satnam Alag |
| Chief Scientific Officer and President of Global Clinical & Medical Affairs | Harpal S. Kumar M.A., M.B.A., MEng |
Major Backers & Investors (GRAL)
Notable institutional backers of Grail, Inc. include Baker Bros. Advisors, LP, Farallon Capital Management LLC, Primecap Management Company, according to Nexqual as of July 25, 2026 at 20:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 9.39% |
| Farallon Capital Management LLC | 7.58% |
| Primecap Management Company | 4.3% |
| Deep Track Capital, Lp | 4.01% |
| Sessa Capital IM, L.P. | 4.01% |
| Morgan Stanley | 3.8% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.25% |
| Vanguard Group | 7.82% |
| State Street | 7.72% |
Source: Nexqual, July 25, 2026 at 20:15 UTC.
From Grail, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- The law included certain standards, including that Centers for Medicare and Medicaid Services ("CMS") would establish coverage through a national coverage determination ("NCD") process under "reasonable and necessary" evidentiary requirements.
- We can leverage our proprietary platform for additional applications, including our precision oncology portfolio.
- The commercial opportunity for Galleri is significant, with more than 300 million individuals globally over the age of 50 (our intended use population), including more than 100 million individuals in the United States.
- Our proprietary targeted methylation platform, as well as our growing body of clinical and real-world data, have provided us with unique insights into cancer biology that enable development of products beyond asymptomatic screening.
Partnerships
- We have also begun entering select international markets through distributor partners, including Israel and Canada, and intend to enter South Korea through our partnership with Samsung.
- Under our agreement with the NHS, these results have met certain success criteria and missed others.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WGS | GeneDx Holdings Corp. | USD 59.1 | ▼ 5.59% |
| RVMD | Revolution Medicines, Inc. | USD 189.23 | ▲ 3.39% |
| NTRA | Natera, Inc. | USD 261.99 | ▼ 0.84% |
| GH | Guardant Health, Inc. | USD 147.33 | ▼ 2.27% |
| GPCR | Structure Therapeutics Inc. | USD 49.12 | ▼ 2.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 20:15 UTC. This page is informational and not investment advice.